Industries › Pharma & Medical Devices

What Pharma & Medical Devices organizations are saying about federal rules

293 Pharma & Medical Devices organizations have filed 595 comment letters on 88 proposed federal rules. The most active are Advanced Medical Technology Association (AdvaMed), Biotechnology Innovation Organization (BIO), Amgen Inc.. Search their letters.

Comment letters

595

Organizations

293

Rules commented on

88

Agencies they write to most

HHS 497 CMS 442 Office of the Secretary (Health and Human Services Department) 49 DOJ 24 Office of Inspector General (Health and Human Services Department) 17 FWS 15 Interior Department 15 Drug Enforcement Administration 14 SEC 11 NRC 10 USDA 9 Commerce Department 6 FTC 6 Office of the Secretary (Agriculture Department) 6 DOT 5

Most active organizations

1. Advanced Medical Technology Association (AdvaMed) · 19 letters on 18 rules
2. Biotechnology Innovation Organization (BIO) · 13 letters on 12 rules
3. Amgen Inc. · 11 letters on 10 rules
4. Pharmaceutical Research and Manufacturers of America (PhRMA) · 11 letters on 10 rules
5. AbbVie · 10 letters on 10 rules
6. Johnson & Johnson · 10 letters on 9 rules
7. The Pharmaceutical Care Management Association (PCMA) · 9 letters on 9 rules
8. McKesson Corporation · 8 letters on 8 rules
9. Pfizer, Inc. · 8 letters on 7 rules
10. Eisai Inc. · 7 letters on 6 rules
11. Academy of Managed Care Pharmacy (AMCP) · 6 letters on 6 rules
12. American Therapeutic Recreation Association · 6 letters on 6 rules
13. Bristol Myers Squibb · 6 letters on 5 rules
14. Center for Biological Diversity and Humane World for Animals · 6 letters on 1 rule
15. Eli Lilly and Company · 6 letters on 6 rules
16. Guardant Health · 6 letters on 6 rules
17. Massachusetts Biotechnology Council (MassBio) · 6 letters on 5 rules
18. National Pharmaceutical Council · 6 letters on 6 rules
19. Sanofi · 6 letters on 5 rules
20. Adult Vaccine Access Coalition · 5 letters on 5 rules
21. American Association for Homecare · 5 letters on 4 rules
22. Center for Biological Diversity, Healthy Gulf, and the Sierra Club · 5 letters on 1 rule
23. CSL Behring · 5 letters on 5 rules
24. Genentech · 5 letters on 5 rules
25. Gilead Sciences, Inc. · 5 letters on 5 rules
26. National Association of Specialty Pharmacy · 5 letters on 5 rules
27. Orthotic and Prosthetic Alliance · 5 letters on 4 rules
28. Senior Care Pharmacy Coalition (SCPC) · 5 letters on 5 rules
29. Teva Pharmaceuticals · 5 letters on 5 rules
30. The Association for Accessible Medicines (AAM) · 5 letters on 5 rules
31. Ardelyx, Inc. · 4 letters on 4 rules
32. Biogen · 4 letters on 4 rules
33. Boehringer Ingelheim · 4 letters on 4 rules
34. Plasma Protein Therapeutics Association · 4 letters on 4 rules
35. ResearchDx, Inc. · 4 letters on 1 rule
36. Takeda Pharmaceuticals · 4 letters on 4 rules
37. United Therapeutics Corporation · 4 letters on 2 rules
38. Vantive · 4 letters on 3 rules
39. Abbott · 3 letters on 3 rules
40. Akebia Therapeutics · 3 letters on 3 rules
41. AstraZeneca · 3 letters on 3 rules
42. Biocom · 3 letters on 3 rules
43. Caris Life Sciences · 3 letters on 2 rules
44. CSL Vifor · 3 letters on 3 rules
45. Dexcom, Inc. · 3 letters on 3 rules
46. Fresenius Kabi · 3 letters on 3 rules
47. Illumina, Inc. · 3 letters on 3 rules
48. Incubate Coalition · 3 letters on 3 rules
49. Lundbeck Pharmaceuticals LLC · 3 letters on 3 rules
50. Medical Device Manufacturers Association (MDMA) · 3 letters on 3 rules

Rules that drew the most letters from this industry

• Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program CMS-2026-2080 · CMS · 63 letters
• Global Benchmark for Efficient Drug Pricing (GLOBE) Model CMS-2025-1889 · CMS · 57 letters
• Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model CMS-2025-1888 · CMS · 53 letters
• Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs; Including the Hospital Outpatient Quality Reporting Program and Ambulatory Surgical Center Quality Program; Request for Information on Strengthening the Standardization and Comparability of Hospital Price Transparency (HPT) Data; Prior Authorization; Accrediting Organization (AO) Deeming for Emergency Medical Treatment and Labor Act (EMTALA); and Notices of Closure of Teaching Hospitals and Opportunities To Apply for Available Slots CMS-2026-2344 · CMS · 43 letters
• Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program; Correction CMS-2025-0304 · CMS · 31 letters
• Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; Interoperability Standards and Prior Authorization for Drugs for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, and Issuers of Qualified Health Plans on the Federally-Facilitated Exchanges CMS-2026-1255 · Office of the Secretary (Health and Human Services Department) · 31 letters
• Request for Information; Clinical Laboratory Improvement Amendments of 1988 (CLIA) Regulations CMS-2026-2345 · CMS · 30 letters
• Request for Information (RFI) Related to Comprehensive Regulations To Uncover Suspicious Healthcare (CRUSH) CMS-2026-0826 · CMS · 20 letters
• Calendar Year 2027 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the Expanded HH Value-Based Purchasing Model; Medicare Provider Enrollment, Durable Medical Equipment (DME), and DME, Prosthetics, Orthotics, and Supplies (DMEPOS) Policies CMS-2026-2311 · CMS · 19 letters
• Medicare Program; Ensuring Safety Through Domestic Security With Made in America Personal Protective Equipment (PPE) and Essential Medicine Procurement by Medicare Participating Hospitals CMS-2026-0298 · CMS · 18 letters
• Request for Information; Comprehensive Review of the Essential Health Benefits Framework and Typical Employer Plan Standard CMS-2026-2081 · HHS · 15 letters
• Request for Information (RFI): Pharmacy Benefit Manager Compensation and Data Collection CMS-2026-2212 · CMS · 12 letters
• Medicare Program; CY 2027 Changes to the End-Stage Renal Disease (ESRD) Prospective Payment System, Acute Kidney Injury Dialysis (AKI) Payment, and ESRD Quality Incentive Program CMS-2026-2245 · CMS · 11 letters
• Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model CMS-2025-0240 · CMS · 8 letters
• Reducing Barriers to Medical Use Licensing NRC-2025-1237 · NRC · 8 letters
• Health Data, Technology, and Interoperability: Patient Engagement, Information Sharing, and Public Health Interoperability HHS-ONC-2024-0010 · Office of the Secretary (Health and Human Services Department) · 7 letters
• Medicare and State Health Care Programs: Fraud and Abuse; Request for Information Regarding the Federal Anti-Kickback Statute and Beneficiary Inducements CMP HHSIG-2026-0001 · Office of Inspector General (Health and Human Services Department) · 7 letters
• Medicare and State Health Care Programs: Fraud and Abuse; Request for Information Regarding the Federal Anti-Kickback Statute and Beneficiary Inducements CMP HHSIG-2026-0034 · Office of Inspector General (Health and Human Services Department) · 7 letters
• Endangered and Threatened Wildlife and Plants; Listing the Giraffe FWS-HQ-ES-2024-0157 · FWS · 6 letters
• Endangered and Threatened Wildlife and Plants; Regulations for Eleven Species Treated as Listed Due to Similarity of Appearance FWS-HQ-ES-2025-0176 · FWS · 6 letters
• Medicare and Medicaid Programs; CY 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program; and Medicare Overpayments CMS-2024-0256 · CMS · 6 letters
• Provisions Pertaining to Preventing Access to U.S. Sensitive Personal Data and Government-Related Data by Countries of Concern or Covered Persons DOJ-NSD-2024-0004 · DOJ · 6 letters
• Revision of Applications for Manufacturing and Procurement Quotas DEA-2026-0793 · Drug Enforcement Administration · 6 letters
• Medicare Program; Alternative Payment Model Updates and the Increasing Organ Transplant Access (IOTA) Model CMS-2025-1690 · CMS · 5 letters
• Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, Conditions for Coverage for End-Stage Renal Disease Facilities, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model CMS-2024-0189 · CMS · 5 letters

Letters by year

Latest letters